Company: SXTPW
Filing Date: 2025-03-27
Form Type: 10-K
Source: 0001013762-25-003343
Chunk: 1768

Company: 60 DEGREES PHARMACEUTICALS, INC.
Filing Date: 2025-03-27
Form: 10-K
Item: Item 7A
Chunk 1768
---
 on July 14, 2023:

oThe Company issued an aggregate of 28,460 shares of common stock upon conversion of the Company’s outstanding debt obligations as follows: (i) 6,404 shares issued to the holders of the 2022 and 2023 Bridge Notes and the Related Party Notes, (ii) 3,583 shares issued pursuant to the Xu Yu Note, including the Amendment, and (iii) 18,473 shares issued to Knight upon conversion of the principal amount of the Convertible Knight Loan, in each case at the conversion prices detailed in Note 8.

oThe Company issued 488 shares of common stock to BioIntelect as deferred equity compensation valued in the amount of $155,000.

In July 2023, the Company issued an aggregate
of 3,075 shares of common stock upon the exercise of (i) 525 Bridge Warrants (as defined below), (ii) 1,000 Non-tradeable Warrants, and
(iii) 1,550 Tradeable Warrants.

On July 25, 2023, the Company converted 2,162
shares of Series A Preferred Stock held by Knight into 760 shares of common stock.

F-20

On December 28, 2023, the Company issued 176
shares of common stock to Red Chip as deferred equity compensation valued in the amount of $40,000 based on the 30-day average price
of the publicly traded common shares after the IPO, as required by the terms of the investment relations consulting agreement signed
in March 2023.

On January 29, 2024, the Company, entered into
an Underwriting Agreement with WallachBeth Capital LLC, relating to the Company’s public offering (the “January 2024 Offering”)
of 87,682 units at an offering price of $23.10 per unit and 16,652 pre-funded units at an offering price of $22.50 per pre-funded unit.
Each unit consisted of one share of common stock and one warrant exercisable for one share of common stock (the “January 2024 Warrants”).
Each pre-funded unit consists of one pre-funded warrant exercisable for one share of common stock (the “January 2024 Pre-Funded
Warrants”) and one warrant identical to the January 2024 Warrants included in the units. The January 2024 Pre-Funded Warrants have
an exercise price of $0.60 per share,